BrainHealth's SMART methodology helps patients make more informed treatment decisions

September 23, 2020

DALLAS (September 23, 2020) - Researchers at Center for BrainHealth, part of The University of Texas at Dallas, collaborated with scientists at the University of North Carolina at Chapel Hill to examine whether the Strategic Memory Advanced Reasoning Training (SMART) program affects people's abilities to make informed decisions about their medical treatment options. Patients with rheumatoid arthritis, in particular, are often reluctant to take antirheumatic drugs because of perceptions about the drugs' risks and benefits. The findings from this study point to an approach that helps these patients, and other people, make more informed decisions about their health.

The study, accepted for publication in Arthritis Care & Research (August 2020), was authored by lead researcher Susan J. Blalock, PhD, a now-retired professor from the University of North Carolina at Chapel Hill, and a research team that featured Sandra Bond Chapman, PhD, founder and chief director of the Center for BrainHealth, and Molly Keebler, former head of community programs at the Center for BrainHealth.

SMART teaches evidence-based strategies and techniques that improve strategic thinking, increase productivity and foster innovation. It was developed and tested by BrainHealth researchers over the past three decades.

The findings build on previous work that suggests the SMART program helps people understand the gist, or bottom-line meaning, of complex information. As part of the study, patients with rheumatoid arthritis were asked questions about how they value the risks and rewards of certain antirheumatic drugs. Six months after they participated in the SMART program, participants that initially had inadequate knowledge of the risks and rewards of treatment options made more informed decisions because they became more knowledgeable about the drugs.

The SMART protocol helps improve gist reasoning abilities - how well people can understand the overall gist or essence of complex information such as medication pamphlets and doctor's recommendations. "Rather than getting overwhelmed by the immense number of warnings, possible risks and outcomes, participants learn to focus on the major facts rather than all the less relevant details, to reach an informed decision aligned with their personal values," said Chapman.

This research has broader implications, such that the SMART methodology could help others with a variety of chronic conditions strategically focus on key inputs to make more informed decisions consistent with their belief systems about their health.

"We helped empower people to ask questions and focus more effectively on the most important facts within complex information by following a SMART protocol. We got them thinking about the big picture and gave them the confidence to be informed users of medical advice - actively engaged in making decisions about their healthcare," said Chapman.
The Center for BrainHealth, part of The University of Texas at Dallas, is a research institute committed to enhancing, preserving and restoring brain health across the lifespan. Scientific exploration at the Center for BrainHealth is leading edge, improving lives today and translating groundbreaking discoveries into practical clinical application. By delivering science-based innovations that enhance how people think, work and live, the Center and its Brain Performance Institute™ are empowering people of all ages to unlock their brain potential. Major research areas include the use of functional and structural neuroimaging techniques to better understand the neurobiology supporting cognition and emotion in health and disease.

Center for BrainHealth

Related Rheumatoid Arthritis Articles from Brightsurf:

Reducing dementia in patients with rheumatoid arthritis
The incidence of dementia in patients with rheumatoid arthritis is lower in patients receiving biologic or targeted synthetic disease modifying antirheumatic drugs (DMARDs) than in patients who receive conventional synthetic DMARDs, according to a new study.

Is rheumatoid arthritis two different diseases?
While disease activity improves over time for most rheumatoid arthritis (RA) patients, long-term outcomes only improve in RA patients with autoantibodies, according to a new study published this week in PLOS Medicine by Xanthe Matthijssen of Leiden University Medical Center, Netherlands, and colleagues.

Does the Mediterranean diet protect against rheumatoid arthritis?
Previous research has demonstrated a variety of health benefits associated with the Mediterranean diet, which is rich in olive oil, cereals, fruit and vegetables, fish, and a moderate amount of dairy, meat, and wine.

Reducing corticosteroid use in rheumatoid arthritis
Is the long-term use of glucocorticoids essential in people with chronic inflammatory diseases such as rheumatoid arthritis, or can early discontinuation prevent characteristic side effects?

Rheumatoid arthritis patients under treatment with methotrexate
Patients with rheumatoid arthritis (RA) often suffer from what is referred to as interstitial lung disease (ILD).

Rheumatoid arthritis -- can its onset be delayed or prevented?
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that leads to significant health issues as well as high treatment costs.

Disease burden in osteoarthritis is similar to rheumatoid arthritis
Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment.

Prospect of a new treatment for rheumatoid arthritis
An international research group led by Charité -- Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.

Can rare lymphocytes combat rheumatoid arthritis?
Immunologists at Friedrich-Alexander-Universität Erlangen-Nürnberg have demonstrated that ILC2, a group of rare lymphoid cells, play a key role in the development of inflammatory arthritis.

Rheumatoid arthritis meets precision medicine
Scientists are bringing precision medicine to rheumatoid arthritis for the first time by using genetic profiling of joint tissue to see which drugs will work for which patients, reports a new multi-site study.

Read More: Rheumatoid Arthritis News and Rheumatoid Arthritis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to